2024
A review of the kappa opioid receptor system in opioid use
Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, PMCID: PMC12179786, DOI: 10.1016/j.neubiorev.2024.105713.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsKappa opioid receptor systemKappa-opioid receptorsOUD subjectsKappa-opioid receptor expressionOpioid withdrawal symptomsWithdrawal symptomsDynorphin levelsPeripheral blood lymphocytesOpioid useDrug-seeking/taking behaviorAnti-reward systemsKappa-opioid receptor antagonistClinical studiesCerebrospinal fluidOpioid receptor systemKOR/dynorphin systemDisorder subjectsOpioid receptorsOpioid intoxicationBlood lymphocytesReceptor systemOpioidWeb of ScienceClinical roleDynorphin
2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityT-DXdUSC patientsUSC cell linesTrastuzumab deruxtecanSerous carcinomaHER2 expressionClinical trialsRecurrent uterine serous carcinomaTopoisomerase I inhibitor payloadSignificant antibody-dependent cellular cytotoxicityCell linesMultiple tumor indicationsPrimary USC cell linesLow HER2 expressionFuture clinical trialsHigh recurrence ratePeripheral blood lymphocytesERBB2 gene amplificationGrowth suppressionHER2-overexpressing cell linesTumor growth suppressionOverall survivalStandard chemotherapy
2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic Agents, AlkylatingBystander EffectCarcinoma, Ovarian EpithelialCell Line, TumorDuocarmycinsFemaleHumansImmunotoxinsIndolesMaytansineMiceMice, SCIDMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPyrrolidinonesRandom AllocationReceptor, ErbB-2TrastuzumabXenograft Model Antitumor AssaysConceptsHER2/neu expressionAntibody-dependent cellular cytotoxicityEpithelial ovarian cancerLow HER2/neu expressionPeripheral blood lymphocytesHER2/neu 3Antibody-drug conjugatesT-DM1Neu expressionEOC cell linesNeu 3HER2-targeting antibody-drug conjugateNovel antibody-drug conjugateNovel HER2-targeting antibody-drug conjugateEpithelial ovarian carcinomaOvarian cancer xenograftsAnti-tumor activityCell linesEOC xenograftsTrastuzumab emtansineCancer xenograftsBlood lymphocytesOvarian cancerOvarian carcinomaSYD985
2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal Of Experimental & Clinical Cancer Research 2015, 34: 123. PMID: 26474755, PMCID: PMC4609066, DOI: 10.1186/s13046-015-0241-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, BispecificAntigens, NeoplasmAntineoplastic AgentsCarcinosarcomaCD3 ComplexCell Adhesion MoleculesCell Line, TumorCell ProliferationCoculture TechniquesCytokinesCytotoxicity, ImmunologicDrug Resistance, NeoplasmEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansKiller Cells, NaturalLymphocyte ActivationMiddle AgedOvarian NeoplasmsT-Lymphocytes, CytotoxicUterine NeoplasmsConceptsCS cell linesPeripheral blood lymphocytesT cellsEpCAM/CD3-bispecific antibodyCell linesT cell-mediated killingT-cell activation markersFlow cytometryCD3 bispecific antibodyChromium release assaysT cell proliferationCarcinosarcoma cell lineFlow cytometry assaySingle-chain antibody constructCS cellsPositive cell linesH 51CrOvarian carcinosarcomaPleural effusionActivation markersGynecologic tumorsPoor prognosisCS patientsRecurrent/Blood lymphocytesSolitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BispecificAntigens, NeoplasmAntineoplastic AgentsAscitic FluidCarcinoma, PapillaryCD3 ComplexCD4-Positive T-LymphocytesCell Adhesion MoleculesCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesCytokinesCytotoxicity, ImmunologicEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansLymphocyte ActivationNeoplasms, Cystic, Mucinous, and SerousT-Lymphocytes, CytotoxicUterine NeoplasmsConceptsUterine serous carcinoma cell linesUterine serous carcinomaEpithelial cell adhesion moleculeCell adhesion molecule expressionCarcinoma cell linesChromium release assaysSerous carcinoma cellsPeripheral blood lymphocytesAdhesion molecule expressionCell adhesion moleculeEpithelial cell adhesion molecule (EpCAM) expressionSerous carcinomaAdhesion moleculesBlood lymphocytesMolecule expressionT cellsAscitic fluidCell linesTumor-associated T cellsT cell-mediated killingT-cell activation markersFlow cytometryTumor cellsCarcinoma cellsRobust immunologic responses
2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2014, 121: 403-412. PMID: 25251053, PMCID: PMC4304922, DOI: 10.1002/cncr.29062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, BispecificAntigens, NeoplasmCarcinoma, Ovarian EpithelialCD3 ComplexCell Adhesion MoleculesCell Line, TumorCytotoxicity, ImmunologicDrug Resistance, NeoplasmEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsT-LymphocytesConceptsOvarian cancer cell linesPeripheral blood lymphocytesTumor cellsCancer cell linesFlow cytometryBlood lymphocytesCell linesMalignant cellsChemotherapy-resistant cell linesChemotherapy-resistant ovarian cancerT cell-mediated killingT-cell activation markersCell-mediated cytotoxicity assayEpCAM expressionPrimary ovarian cancer cell linesFresh ovarian tumorsChemotherapy-resistant diseaseCD3 bispecific antibodyTumor-associated lymphocytesEpithelial ovarian carcinoma cell linesT cell cytotoxicityChromium release assaysFresh tumor cellsOvarian tumor cell linesOvarian tumor cellsMultiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Beard R, Zheng Z, Lagisetty K, Burns W, Tran E, Hewitt S, Abate-Daga D, Rosati S, Fine H, Ferrone S, Rosenberg S, Morgan R. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. Journal For ImmunoTherapy Of Cancer 2014, 2: 25. PMID: 25197555, PMCID: PMC4155770, DOI: 10.1186/2051-1426-2-25.Peer-Reviewed Original ResearchCSPG4 expressionChimeric antigen receptorChondroitin sulfate proteoglycan 4Peripheral blood lymphocytesGlioblastoma cancer stem cellsCancer stem cellsTumor antigensStem cellsCancer histologyAntigen receptorBreast cancerExpression of chondroitin sulfate proteoglycan-4CAR-transduced T cellsCell linesChimeric antigen receptor constructTriple-negative breast cancerTreatment of metastatic cancerCAR-based immunotherapyOff-tumor toxicityResected human tumorsGamma-retroviral vectorsDevelopment of immunotherapyRT-PCRTarget cell linesReverse-phase protein array
2013
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells
Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, Huttner AJ, Kleinstein SH, Lee JY, Stern JN, Yaari G, Lovato L, Cronk KM, O'Connor KC. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-Oncology 2013, 15: 1479-1490. PMID: 23978377, PMCID: PMC3813416, DOI: 10.1093/neuonc/not110.Peer-Reviewed Original ResearchConceptsTumor-infiltrating B cellsImmune cell infiltratesT cell repertoireCell infiltrateB cellsT cellsCell repertoireAntigen experienceImmune checkpoint molecules PD-1Memory/effector T cellsCheckpoint molecules PD-1Antigen-driven B cell responsesEffector T cell populationsTumor microenvironmentT-cell infiltratesRegulatory T cellsEffector T cellsT-cell phenotypeT cell populationsB cell responsesPeripheral blood lymphocytesAntigen-experienced CD4Cell populationsB cell populationsB cell repertoireRandomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Dudley M, Gross C, Somerville R, Hong Y, Schaub N, Rosati S, White D, Nathan D, Restifo N, Steinberg S, Wunderlich J, Kammula U, Sherry R, Yang J, Phan G, Hughes M, Laurencot C, Rosenberg S. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal Of Clinical Oncology 2013, 31: 2152-2159. PMID: 23650429, PMCID: PMC3731980, DOI: 10.1200/jco.2012.46.6441.Peer-Reviewed Original ResearchConceptsYoung tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesAdoptive cell therapyCD4(+) lymphocytesCell therapyInterleukin-2High-dose IL-2 therapyAutologous tumor-infiltrating lymphocytesHigh-dose interleukin-2Infusion tumor-infiltrating lymphocytesResponse to autologous tumorTIL infusionIL-2 therapyImmunologic end pointsInterferon-gamma secretionSubgroup of patientsPeripheral blood lymphocytesResponse to treatmentLymphodepleted patientsLymphodepleting chemotherapyTIL productsTIL therapyAutologous tumorDesign trialMetastatic melanoma
2012
456P Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results
Adjei A, LoRusso P, Ribas A, Sosman J, Dy G, Chmielowski B, Lipman P, Zhou X, Gangolli E, Bozón V. 456P Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results. Annals Of Oncology 2012, 23: ix158. DOI: 10.1016/s0923-7534(20)33014-3.Peer-Reviewed Original ResearchDose-limiting toxicityDrug-related AEsAdvanced solid tumorsAnti-tumor activityTAK-733Solid tumorsECOG PS 0Oral MEK inhibitorDose-escalation studyMedian age 58Non-hematologic malignanciesPeripheral blood lymphocytesCycle 1Multiple xenograft modelsEvaluable ptsStable diseasePartial responsePS 0Dose escalationEvaluable tumorsAdvisory BoardBlood lymphocytesAge 58Blood samplesXenograft model
2009
Generation and characterization of chicken bone marrow‐derived dendritic cells
Wu Z, Rothwell L, Young J, Kaufman J, Butter C, Kaiser P. Generation and characterization of chicken bone marrow‐derived dendritic cells. Immunology 2009, 129: 133-145. PMID: 19909375, PMCID: PMC2807494, DOI: 10.1111/j.1365-2567.2009.03129.x.Peer-Reviewed Original ResearchConceptsBone marrow-derived dendritic cellsChicken bone marrow-derived dendritic cellsMarrow-derived dendritic cellsDendritic cellsPeripheral blood lymphocytesMajor histocompatibility complexChBM-DCsBone marrow-derived professional antigen-presenting cellsIn vitro generation of dendritic cellsInterleukin-4Generation of dendritic cellsProfessional antigen-presenting cellsStimulate naive T cellsGranulocyte-macrophage colony-stimulating factorSurface expression of CD40Morphology of dendritic cellsEffective T cell stimulationAntigen-presenting cellsNaive T cellsExpression of CD40Bone marrow cellsColony-stimulating factorFluorescent bead uptakeT cell stimulationIn vitro generationHuman Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines
Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. Journal Of Virology 2009, 83: 6779-6789. PMID: 19386711, PMCID: PMC2698533, DOI: 10.1128/jvi.02443-08.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCancer VaccinesCapsid ProteinsCell Line, TumorDendritic CellsFemaleGene Expression ProfilingHuman papillomavirus 16HumansMiddle AgedOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus InfectionsRepressor ProteinsRNA, ViralT-Lymphocytes, CytotoxicUterine Cervical NeoplasmsYoung AdultConceptsCervical cancer patientsCytotoxic T lymphocytesAutologous tumor cellsCancer patientsDendritic cellsT lymphocytesL1 VLPsCervical cancerTumor cellsE7 RNADendritic cell-based therapeutic vaccineE7-specific cytotoxic T lymphocytesHPV-16 positive cervical cancerCell-mediated immune responsesExpression levelsAutologous dendritic cellsHPV-16 VLPPromising prophylactic vaccineE7-specific CD8Human papillomavirus infectionT lymphocyte responsesStrong cytolytic activityTreatment of patientsPeripheral blood lymphocytesPrimary cervical tumors
2008
The human T cell receptor Vβ repertoire of normal peripheral blood lymphocytes before and after mitogen stimulation
WONG F, HIBBERD M, WEN L, MILLWARD B, DEMAINF A. The human T cell receptor Vβ repertoire of normal peripheral blood lymphocytes before and after mitogen stimulation. Clinical & Experimental Immunology 2008, 92: 361-366. PMID: 8387412, PMCID: PMC1554814, DOI: 10.1111/j.1365-2249.1993.tb03405.x.Peer-Reviewed Original ResearchConceptsT cellsMitogen stimulationT cell antigen receptorPolymerase chain reactionT cell receptor Vβ repertoireFlow cytometryNormal peripheral blood lymphocytesMitogen-stimulated T cellsPeripheral blood lymphocytesTCR gene usagePeripheral T cellsT cell linesVβ repertoireUnstimulated T cellsBeta repertoireBlood lymphocytesHealthy individualsPCR methodBeta 6Cell antigen receptorGene usageAntigen receptorBeta 2Beta 5Chain reaction
2007
High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.
Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Montanari F, Rizzi S, Rumi E, Pascutto C, Paulli M, Zuffardi O, Lazzarino M. High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. Blood 2007, 110: 2620. DOI: 10.1182/blood.v110.11.2620.2620.Peer-Reviewed Original ResearchSplenic marginal zone B-cell lymphomaMarginal zone B-cell lymphomaPrognostic categoriesNumber of CNAsB-cell lymphomaCopy number alterationsHCV casesVillous lymphocytesGenetic alterationsAdverse prognostic factorRecent multicentre studyPeripheral blood lymphocytesDifferent prognostic categoriesFrequent copy number alterationsGroups of ptsImmunoglobulin variable heavy chain genesSpecific genetic abnormalitiesSpecific genetic alterationsVariable heavy chain genesAutoimmune backgroundHCV infectionHCV statusPrognostic factorsClinical featuresMulticentre studyOverexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106: 513-520. PMID: 17540437, DOI: 10.1016/j.ygyno.2007.04.028.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityCervical cancer cell linesPeripheral blood lymphocytesComplement-dependent cytotoxicityCancer cell linesEGFR-1Cervical cancerCervical tumorsRecurrent sitesPrimary cervical cancer cell linesCell linesRecurrent/metastatic diseaseTumor cell linesType 1 receptor expressionFlow cytometryFactor type 1 receptorMetastatic cervical cancerCervical cancer patientsType 1 receptorPresence of complementCervical tumor cell linesAttractive therapeutic strategyMetastatic diseaseCervical biopsiesMetastatic sites
2006
E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer
Lin J, Dinney C, Grossman H, Jhamb M, Zhu Y, Spitz, Wu X. E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer. Clinical Genetics 2006, 70: 240-245. PMID: 16922727, DOI: 10.1111/j.1399-0004.2006.00666.x.Peer-Reviewed Original ResearchConceptsSuperficial bladder cancerBladder cancer recurrenceBladder cancerCancer recurrencePromoter polymorphismHazard ratioCaucasian patientsMedian recurrence-free survivalMedical chart reviewRecurrence-free survivalRisk of recurrencePeripheral blood lymphocytesProportional hazards modelHomozygous CC genotypeChart reviewDisease recurrenceSmoking statusTumor recurrenceTumor stageBlood lymphocytesClinical dataCC genotypeHazards modelPatientsRecurrence risk
2004
Methyl‐CpG‐binding domain 2
Zhu Y, Spitz M, Zhang H, Grossman H, Frazier M, Wu X. Methyl‐CpG‐binding domain 2. Cancer 2004, 100: 1853-1858. PMID: 15112265, DOI: 10.1002/cncr.20199.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCase-Control StudiesDNA MethylationDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansLogistic ModelsMaleMolecular Sequence DataOdds RatioProbabilityPrognosisPromoter Regions, GeneticReference ValuesReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerSensitivity and SpecificityUrinary Bladder NeoplasmsConceptsMBD2 expressionCarcinoma riskCurrent case-control studyReverse transcription polymerase chain reaction assaysCase-control studyPeripheral blood lymphocytesQuantitative reverse transcription-polymerase chain reaction assaysTranscription-polymerase chain reaction assaysMessenger RNA expressionReal-time quantitative reverse transcription-polymerase chain reaction assaysControl patientsLight smokersCase patientsHeavy smokersUnderlying molecular mechanismsTumor tissue typesBlood lymphocytesChain reaction assaysProtective effectProtective roleQuartile distributionDomain 2 proteinOlder individualsTumor developmentYoung individualsRestoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
Santin A, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman J, Cannon M, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. DOI: 10.1136/ijgc-00009577-200401000-00008.Peer-Reviewed Original ResearchPeripheral blood lymphocytesAdvanced ovarian cancerAdvanced ovarian cancer patientsDendritic cellsOvarian cancer patientsOvarian cancerT cellsCancer patientsClass ILymphoblastoid cell linesTumor antigen-loaded dendritic cellsTumor lysate-pulsed dendritic cellsTumor-specific T-cell responsesAutologous ovarian cancer cellsAutologous tumor target cellsDC stimulationLysate-pulsed dendritic cellsType 1 cytokine biasAntigen-loaded dendritic cellsAnti-HLA class IAutologous Epstein-Barr virusSpecific human leukocyte antigenProfessional antigen presenting cellsAdoptive T-cell immunotherapyAutologous tumor cellsRestoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
SANTIN A, BELLONE S, PALMIERI M, BOSSINI B, CANE S, BIGNOTTI E, ROMAN J, CANNON M, PECORELLI S. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. DOI: 10.1111/ijgc-00009577-200401000-00008.Peer-Reviewed Original ResearchCD8+ T cellsAdvanced ovarian cancerPeripheral blood lymphocytesAdvanced ovarian cancer patientsTumor-infiltrating lymphocytesTumor infiltrationOvarian cancer patientsCytotoxic T lymphocytesDendritic cell stimulationOvarian cancerT cellsLymphoblastoid cell linesInfiltrating lymphocytesDendritic cellsKilling of autologous tumor cellsTumor-specific cytotoxic T lymphocytesTumor-specific T-cell responsesAnti-HLA class I mAbCD8+ T cell populationsCancer patientsAutologous ovarian cancer cellsAutologous tumor target cellsCD8+ CTL responsesLevels of CD56 expressionTumor antigen-loaded DCRestoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. PMID: 14764031, DOI: 10.1111/j.1048-891x.2004.014175.x.Peer-Reviewed Original ResearchConceptsPeripheral blood lymphocytesAdvanced ovarian cancerAdvanced ovarian cancer patientsDendritic cellsOvarian cancer patientsOvarian cancerT cellsCancer patientsClass ILymphoblastoid cell linesTumor antigen-loaded dendritic cellsTumor lysate-pulsed dendritic cellsTumor-specific T-cell responsesAutologous ovarian cancer cellsAutologous tumor target cellsDC stimulationLysate-pulsed dendritic cellsType 1 cytokine biasAntigen-loaded dendritic cellsAnti-HLA class IAutologous Epstein-Barr virusIFN-gamma-positive cellsSpecific human leukocyte antigenProfessional antigen presenting cellsAdoptive T-cell immunotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply